Effects of stellate ganglion block on vasomotor symptoms: Findings from a randomized controlled clinical trial in postmenopausal women

Menopause

Volumn 21, Issue 8, 2014, Pages 807-814

  Walega, David R ^a   Rubin, Leah H ^b   Banuvar, Suzanne ^a   Shulman, Lee P ^a   Maki, Pauline M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Hot flashes; Hot flushes; Menopause; Nonhormonal treatment.; Stellate ganglion injections; Vasomotor symptoms

Indexed keywords

BUPIVACAINE; SODIUM CHLORIDE; LOCAL ANESTHETIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ANESTHESIOLOGICAL PROCEDURE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HORNER SYNDROME; HOT FLUSH; HUMAN; LIFE SATISFACTION; LIKERT SCALE; MIDDLE AGED; NIGHT SWEAT; OUTCOME ASSESSMENT; PITTSBURGH SLEEP QUALITY INDEX; PLACEBO EFFECT; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SHAM PROCEDURE; SKIN CONDUCTANCE; SLEEP DISORDER; SLEEP QUALITY; STELLATE GANGLION BLOCK; SYMPATHETIC BLOCKING; VASOMOTOR DISORDER; VASOMOTOR SYMPTOM; WELLBEING; AGED; HOT FLASHES; NERVE BLOCK; PATHOLOGY; SEVERITY OF ILLNESS INDEX; STELLATE GANGLION; TREATMENT OUTCOME;

ADULT; AGED; ANESTHETICS, LOCAL; AUTONOMIC NERVE BLOCK; BUPIVACAINE; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SEVERITY OF ILLNESS INDEX; STELLATE GANGLION; TREATMENT OUTCOME;

EID: 84905018650     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000194     Document Type: Article

References (35)

1. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86, discussion 123-133.
2. de Villiers TJ, Gass ML, Haines CJ, et al. Global Consensus Statement on menopausal hormone therapy. Maturitas 2013;74:391-392.
3. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978.
4. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebocontrolled trial. Lancet 2005;366:818-824.
5. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-793.
6. Geller SE, Shulman LP, van Breemen RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156-1166.
7. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869-879.
8. Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist 2011;16:1658-1664.
9. Fisher TE, Chervenak JL. Lifestyle alterations for the amelioration of hot flashes. Maturitas 2012;71:217-220.
10. Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027-1035.
11. Joffe H, Guthrie KA, Larson J, et al. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network. Menopause 2013;20: 261-268.
12. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071.
13. Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008;9:523-532.
14. Pachman DR, Barton D, Carns PE, et al. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer 2011;19:941-947.
15. Haest K, Kumar A, Van Calster B, et al. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Ann Oncol 2012;23:1449-1454.
16. van Gastel P, Kallewaard JW, van der Zanden M, de Boer H. Stellateganglion block as a treatment for severe postmenopausal flushing. Climacteric 2013;16:41-47.
17. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Womens Health Across the Nation (SWAN). J Affect Disord 2007;103:267-272.
18. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-382.
19. Carpenter JS, Guthrie KA, Larson JC, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril 2012;97: 1399-1404.e1.
20. Carpenter JS, Burns DS, Wu J, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med 2013;28:193-200.
21. Painovich JM, Shufelt CL, Azziz R, et al. A pilot randomized, singleblind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause. Menopause 2012; 19:54-61.
22. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998;16:327-333.
23. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
24. Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 1989;26:573-579.
25. Carpenter JS, Andrykowski MA, Freedman RR, Munn R. Feasibility and psychometrics of an ambulatory hot flash monitoring device. Menopause 1999;6:209-215.
26. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
27. Utian WH, Janata JW, Kingsberg SA, Schluchter M, Hamilton JC. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002;9:402-410.
28. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-274.
29. Mulvaney SW, McLean B, de Leeuw J. The use of stellate ganglion block in the treatment of panic/anxiety symptoms with combat-related posttraumatic stress disorder; preliminary results of long-term follow-up: a case series. Pain Pract 2010;10:359-365.
30. Wulf H, Maier C. [Complications and side effects of stellate ganglion blockade. Results of a questionnaire survey]. Anaesthesist 1992;41: 146-151.
31. Diwadkar VA, Murphy ER, Freedman RR. Temporal sequencing of brain activations during naturally occurring thermoregulatory events [published online ahead of print June 19, 2013]. Cereb Cortex.
32. Westerhaus MJ, Loewy AD. Central representation of the sympathetic nervous system in the cerebral cortex. Brain Res 2001;903:117-127.
33. Lipov EG, Joshi JR, Sanders S, Slavin KV. A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Med Hypotheses 2009;72:657-661.
34. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007;12:124-135.
35. Maki PM, Rubin LH, Fornelli D, et al. Effects of botanicals and combined hormone therapy on cognition in postmenopausal women. Menopause 2009;16:1167-1177.